Tabuk Pharmaceuticals was established in 1994 in Riyadh, The Kingdom of Saudi Arabia. Grew from being a family owned business to the largest private Saudi Pharmaceutical Company that Develops, manufactures, markets and distributes branded generic pharmaceutical and under-licensed products, with a strong focus on the Middle East and Africa. Tabuk Pharmaceuticals Operates in 17 countries in the Middle East and Africa, supported by four active manufacturing sites and over 2,400 employees.
Tabuk Pharmaceuticals business model is to develop and market a wide range of branded generic and under-licensed products in various dosage forms. In addition to, manufacturing high-quality products at sterile and non-sterile cephalosporin and non-cephalosporin plants.
Tabuk Pharmaceuticals key strengths are, the strong manufacturing capabilities in Four state of the art manufacturing sites in Saudi Arabia, Sudan, and Algeria. As well as, the talented Research and Development center Experienced team responsible for injecting new products to Tabuk’s portfolio through adopting the latest technologies.
Tabuk Pharmaceuticals has a growing and wide diversified portfolio in major therapeutic areas and several partnerships with global players for under licensed products. Leading position in Saudi Arabian market Ranked as the largest privately-owned pharmaceutical company in Saudi Arabia with a leading position in both private and public sectors. Strong regional presence with dedicated sales and marketing teams in 17 countries in Middle East and Africa.
Tabuk Pharmaceuticals are planning to enhance the access to patent products through alliances with multinational companies to produce and market patent products in the Middle East and Africa.